Avexa is a biotech with a focus on R&D of drugs for infectious diseases. Avexa’s two key projects involve HIV and antibiotic-resistant infections. The company’s lead program is for apricitabine, an anti-HIV drug in-licensed from Shire BioChem. Avexa’s HIV project also includes its HIV integrase inhibitor program. Avexa’s primary commercial strategy is to realize the value of its internal projects by achieving definitive value-adding milestones.